CA3201088A1 - Co-agonists of the glp-1 and amylin receptors - Google Patents

Co-agonists of the glp-1 and amylin receptors

Info

Publication number
CA3201088A1
CA3201088A1 CA3201088A CA3201088A CA3201088A1 CA 3201088 A1 CA3201088 A1 CA 3201088A1 CA 3201088 A CA3201088 A CA 3201088A CA 3201088 A CA3201088 A CA 3201088A CA 3201088 A1 CA3201088 A1 CA 3201088A1
Authority
CA
Canada
Prior art keywords
ethoxy
amino
receptor
glp
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3201088A
Other languages
English (en)
French (fr)
Inventor
Thomas Kruse
Anne Louise Bank Kodal
Johnny Madsen
Soren Ostergaard
Wouter Frederik Johan HOGENDORF
Christian Wenzel Tornoe
Alice Ravn Madsen
Lauge Schaffer (deceased)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of CA3201088A1 publication Critical patent/CA3201088A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA3201088A 2020-12-18 2021-12-17 Co-agonists of the glp-1 and amylin receptors Pending CA3201088A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP20215291.4 2020-12-18
EP20215291 2020-12-18
EP21154668 2021-02-02
EP21154668.4 2021-02-02
EP21179810.3 2021-06-16
EP21179810 2021-06-16
PCT/EP2021/086494 WO2022129526A1 (en) 2020-12-18 2021-12-17 Co-agonists of the glp-1 and amylin receptors

Publications (1)

Publication Number Publication Date
CA3201088A1 true CA3201088A1 (en) 2022-06-23

Family

ID=79024591

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3201088A Pending CA3201088A1 (en) 2020-12-18 2021-12-17 Co-agonists of the glp-1 and amylin receptors

Country Status (15)

Country Link
US (2) US12054528B2 (https=)
EP (1) EP4263581A1 (https=)
JP (1) JP7554928B2 (https=)
KR (3) KR20250165665A (https=)
CN (1) CN116669753A (https=)
AU (2) AU2021403851B2 (https=)
CA (1) CA3201088A1 (https=)
CL (1) CL2023001714A1 (https=)
CO (1) CO2023008866A2 (https=)
IL (2) IL303127A (https=)
MX (2) MX2023005707A (https=)
MY (1) MY209195A (https=)
PE (1) PE20231659A1 (https=)
TW (2) TWI850611B (https=)
WO (1) WO2022129526A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3204051A1 (en) 2021-01-20 2022-07-28 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
JP7642830B2 (ja) 2021-09-15 2025-03-10 バイキング・セラピューティクス・インコーポレイテッド 代謝及び肝臓障害の処置のための組成物及び方法
WO2023110833A1 (en) 2021-12-13 2023-06-22 Novo Nordisk A/S Pharmaceutical formulations comprising a cyclodextrin
WO2023187067A1 (en) 2022-03-30 2023-10-05 Novo Nordisk A/S Formulation method
WO2024022465A1 (zh) * 2022-07-29 2024-02-01 杭州九源基因工程有限公司 一种人胰淀素多肽衍生物及其用途
IL318291A (en) * 2022-08-05 2025-03-01 Univ Indiana Res & Tech Corp Glucagon-like peptide 1 receptor antibodies
US12116388B2 (en) 2022-12-22 2024-10-15 Novo Nordisk A/S Amylin receptor agonists
WO2024179606A1 (zh) * 2023-03-02 2024-09-06 甘李药业股份有限公司 一种glp-1化合物的医药用途
KR20240176455A (ko) 2023-06-15 2024-12-24 노보 노르디스크 에이/에스 시클로덱스트린을 포함하는 약학적 제형
TW202540155A (zh) 2023-11-30 2025-10-16 丹麥商諾佛 儂迪克股份有限公司 Glp-1、gip及澱粉素受體之三重促效劑
AU2025214636A1 (en) * 2024-01-29 2026-01-29 Immunwork Inc. Pharmaceutical formulation of glucagon-like peptide -1 receptor agonist peptide for sublingual delivery
EP4721760A1 (en) 2024-10-07 2026-04-08 Adocia Composition comprising a peptide having an isoelectric point of less than 6.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
WO2025172605A1 (en) 2024-02-16 2025-08-21 Adocia Composition comprising a peptide having an isoelectric point of less than 6.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
EP4721761A1 (en) 2024-10-07 2026-04-08 Adocia Composition comprising semaglutide, cagrilintide and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
EP4603079A1 (en) 2024-02-16 2025-08-20 Adocia Composition comprising a peptide having an isoelectric point of less than 6.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
EP4684802A1 (en) 2024-07-23 2026-01-28 Adocia Composition comprising a peptide having an isoelectric point of less than 6.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
EP4684801A1 (en) 2024-07-23 2026-01-28 Adocia Composition comprising semaglutide, cagrilintide and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
EP4603080A1 (en) 2024-02-16 2025-08-20 Adocia Composition comprising semaglutide, cagrilintide and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
WO2025172606A1 (en) 2024-02-16 2025-08-21 Adocia Composition comprising semaglutide, cagrilintide and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
WO2025242620A1 (en) * 2024-05-20 2025-11-27 Medimmune Limited Polypeptide combinations and uses thereof
WO2025264979A1 (en) * 2024-06-21 2025-12-26 I2O Therapeutics, Inc. Compositions comprising pharmaceutically acceptable salts and other derivatives of dual glp-1/amylin receptor agonists and uses thereof
WO2026008836A1 (en) * 2024-07-05 2026-01-08 Novo Nordisk A/S Glp-1 derivatives and uses thereof
WO2026013265A1 (en) 2024-07-12 2026-01-15 Novo Nordisk A/S Novel dipeptide acylating agents
CN120305390B (zh) * 2025-06-18 2025-10-03 杭州思诺达医药科技有限责任公司 一种降血糖的药物制剂

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994008006A1 (en) 1992-09-30 1994-04-14 Zymogenetics, Inc. Human calcitonin receptor
BR122019021416A2 (https=) 2003-09-19 2019-12-21
NZ579621A (en) * 2004-02-11 2011-03-31 Amylin Pharmaceuticals Inc Hybrid polypeptides with selectable properties
WO2007022123A2 (en) 2005-08-11 2007-02-22 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
WO2007109354A2 (en) * 2006-03-21 2007-09-27 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of using same
EP2190872B1 (en) 2007-09-05 2018-03-14 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
WO2009030771A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
EP2416797A4 (en) 2009-04-10 2013-04-24 Amylin Pharmaceuticals Llc AMYLINAGONIST COMPOUNDS FOR OXYGEN ANIMAL MICE
EP2504021A4 (en) * 2009-11-23 2013-05-15 Amylin Pharmaceuticals Llc Polypeptide conjugate
JP6006118B2 (ja) * 2009-12-16 2016-10-12 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アナログ及び誘導体
WO2011084808A2 (en) 2009-12-21 2011-07-14 Amunix Operating Inc. Bifunctional polypeptide compositions and methods for treatment of metabolic and cardiovascular diseases
SI2651398T1 (en) 2010-12-16 2018-04-30 Novo Nordisk A/S SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND SOL N- (8- (2-HYDROXYBENZOIL) AMINO) CAPRICULATE ACIDS
EP2714069A4 (en) 2011-05-25 2015-06-24 Amylin Pharmaceuticals Llc LONG-TERM CONJUGATES WITH TWO HORMONES
WO2012160212A1 (en) 2011-05-25 2012-11-29 Camurus Ab Peptide controlled-release formulations
JP6121992B2 (ja) 2011-06-10 2017-04-26 ノヴォ ノルディスク アー／エス ポリペプチド
AU2012311484B2 (en) * 2011-09-23 2017-04-13 Novo Nordisk A/S Novel glucagon analogues
HRP20181447T1 (hr) 2012-03-22 2018-11-02 Novo Nordisk A/S Pripravci glp-1 peptida i njihova priprava
JP6517690B2 (ja) 2012-06-20 2019-05-22 ノヴォ ノルディスク アー／エス ペプチド及び送達剤を含む錠剤製剤
JP6475233B2 (ja) 2013-06-20 2019-02-27 ノヴォ ノルディスク アー／エス Ｇｌｐ−１誘導体及びその使用
CN104558198A (zh) 2014-07-25 2015-04-29 成都贝爱特生物科技有限公司 GLP-1类似物和amylin类似物的融合蛋白制备及其用途
WO2016034604A1 (en) 2014-09-04 2016-03-10 Novo Nordisk A/S Novel amylin and calcitonin receptor agonist
JP6730278B2 (ja) 2014-11-27 2020-07-29 ノヴォ ノルディスク アー／エス Ｇｌｐ−１誘導体及びその使用
WO2016097108A1 (en) 2014-12-17 2016-06-23 Novo Nordisk A/S Glp-1 derivatives and uses thereof
CN105367664B (zh) * 2015-11-04 2019-09-20 成都贝爱特生物科技有限公司 激活GLP-1受体和Amylin受体双功能作用的融合蛋白制备及其用途
BR102015031283A2 (pt) 2015-12-14 2018-09-18 Univ Rio De Janeiro Bioconjugado de amilina humana ou de análogos de amilinanão agregantes, composição, métodos para a preparação deuma composição, para o tratamento de uma doença oucondição e para estabilizar um composto amilino-mimético, e,medicamento
ES2828526T3 (es) 2016-11-07 2021-05-26 Novo Nordisk As Esteres activos DCHBS de compuestos PEG y sus usos
CN108424460A (zh) 2017-02-13 2018-08-21 成都贝爱特生物科技有限公司 GLP-1类似物和davalintide类似物的融合蛋白制备及其用途
JP6898518B2 (ja) 2018-02-02 2021-07-07 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アゴニスト、ｎ−（８−（２−ヒドロキシベンゾイル）アミノ）カプリル酸の塩及び滑沢剤を含む固形組成物
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
CN115461044B (zh) 2020-04-29 2025-06-10 诺和诺德股份有限公司 包含glp-1激动剂和组氨酸的固体组合物

Also Published As

Publication number Publication date
US20240279299A1 (en) 2024-08-22
IL303127A (en) 2023-07-01
US20230331803A1 (en) 2023-10-19
KR102667196B1 (ko) 2024-05-27
PE20231659A1 (es) 2023-10-17
AU2025248685A1 (en) 2025-10-30
CL2023001714A1 (es) 2024-01-05
AU2021403851B2 (en) 2025-09-25
KR20230019499A (ko) 2023-02-08
JP2023553591A (ja) 2023-12-25
IL325793A (en) 2026-03-01
TW202227474A (zh) 2022-07-16
KR20240074867A (ko) 2024-05-28
TWI850611B (zh) 2024-08-01
WO2022129526A1 (en) 2022-06-23
AU2021403851A9 (en) 2025-03-20
US12054528B2 (en) 2024-08-06
MX2023005707A (es) 2023-07-31
CO2023008866A2 (es) 2023-10-09
KR102884383B1 (ko) 2025-11-14
CN116669753A (zh) 2023-08-29
KR20250165665A (ko) 2025-11-26
JP7554928B2 (ja) 2024-09-20
EP4263581A1 (en) 2023-10-25
AU2021403851A1 (en) 2023-06-15
TW202440619A (zh) 2024-10-16
MY209195A (en) 2025-06-26
MX2025000872A (es) 2025-03-07

Similar Documents

Publication Publication Date Title
JP7554928B2 (ja) Ｇｌｐ－１およびアミリン受容体の共作動薬
TW202415675A (zh) 腸促胰島素(incretin)類似物及其用途
JP6701075B2 (ja) アミリン類似体
US20190134159A1 (en) Amylin analogues
EP2773377B1 (en) Glp-1 receptor agonist peptide gastrin conjugates
CN121975020A (en) Co-agonists of GLP-1 and the amylin receptor
CN121991249A (zh) Glp-1和胰淀素受体的共激动剂
CN121991202A (zh) Glp-1和胰淀素受体的共激动剂
JP7755031B2 (ja) Ｇｌｐ－１、ｇｉｐ、およびアミリン受容体の三重作動薬
BR122024023347A2 (pt) Coagonistas dos receptores glp-1 e amilina, formulação farmacêutica compreendendo os ditos coagonistas e uso terapêutico dos mesmos
US12116388B2 (en) Amylin receptor agonists
EP4638480A1 (en) Amylin receptor agonists
EA042757B1 (ru) Аналоги амилина

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241206

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241206

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241206

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251124

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251124